Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAR: lesigercept in adults with chronic spontaneous urticaria inadequately controlled by H1-antihistamines
2025-524006-14-00Phase 2Authorised
- Sponsor
- Yuhan
- Start
- Apr 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in chronic idiopathic urticaria (CIU) comparing Lesigercept with Placebo (2 arms). Primary endpoint: Change from baseline in UAS7 at Week 12. Planned start Apr 2026; status: authorised.
02
Drugs
YH35324
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2025-524006-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524006-14-00.